- Home
- AACG vs BLRX Comparison
AACG vs BLRX Comparison
Compare AACG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- BLRX
- Stock Information
- Founded
- AACG 1999
- BLRX 2003
- Country
- AACG China
- BLRX Israel
- Employees
- AACG N/A
- BLRX N/A
- Industry
- AACG Other Consumer Services
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- AACG Real Estate
- BLRX Health Care
- Exchange
- AACG Nasdaq
- BLRX Nasdaq
- Market Cap
- AACG 31.9M
- BLRX 36.0M
- IPO Year
- AACG N/A
- BLRX 2011
- Fundamental
- Price
- AACG $1.02
- BLRX $0.46
- Analyst Decision
- AACG
- BLRX Strong Buy
- Analyst Count
- AACG 0
- BLRX 2
- Target Price
- AACG N/A
- BLRX $11.50
- AVG Volume (30 Days)
- AACG 57.6K
- BLRX 410.3K
- Earning Date
- AACG 11-07-2024
- BLRX 11-18-2024
- Dividend Yield
- AACG N/A
- BLRX N/A
- EPS Growth
- AACG N/A
- BLRX N/A
- EPS
- AACG N/A
- BLRX N/A
- Revenue
- AACG $35,747,843.00
- BLRX $17,048,000.00
- Revenue This Year
- AACG N/A
- BLRX N/A
- Revenue Next Year
- AACG N/A
- BLRX N/A
- P/E Ratio
- AACG N/A
- BLRX N/A
- Revenue Growth
- AACG 15.80
- BLRX N/A
- 52 Week Low
- AACG $0.50
- BLRX $0.39
- 52 Week High
- AACG $1.65
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- AACG 58.61
- BLRX 48.89
- Support Level
- AACG $0.98
- BLRX $0.40
- Resistance Level
- AACG $1.06
- BLRX $0.46
- Average True Range (ATR)
- AACG 0.06
- BLRX 0.03
- MACD
- AACG -0.01
- BLRX 0.01
- Stochastic Oscillator
- AACG 66.67
- BLRX 72.96
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments are Overseas art study services, Other educational services and K-12 education assessment and other services. Majority of its revenue comes from Overseas art study services.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.